Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles from Denmark
Based on 374 articles published since 2008
||||

These are the 374 published articles about Psoriasis that originated from Denmark during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15
1 Guideline Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. 2017

Raaby, Line / Zachariae, Claus / Østensen, Monika / Heickendorff, Lene / Thielsen, Peter / Grønbæk, Henning / Skov, Lone / Kyvsgaard, Nini / Madsen, Jakob T / Heidenheim, Michael / Funding, Anne T / Strauss, Gitte / Lindberg, Rune / Iversen, Lars. ·Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. ·Acta Derm Venereol · Pubmed #27958611.

ABSTRACT: Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.

2 Guideline EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. 2017

Agca, R / Heslinga, S C / Rollefstad, S / Heslinga, M / McInnes, I B / Peters, M J L / Kvien, T K / Dougados, M / Radner, H / Atzeni, F / Primdahl, J / Södergren, A / Wallberg Jonsson, S / van Rompay, J / Zabalan, C / Pedersen, T R / Jacobsson, L / de Vlam, K / Gonzalez-Gay, M A / Semb, A G / Kitas, G D / Smulders, Y M / Szekanecz, Z / Sattar, N / Symmons, D P M / Nurmohamed, M T. ·Departments of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade & VU University Medical Center, Amsterdam, The Netherlands. · Department of Rheumatology, Preventive Cardio-Rheuma Clinic, Diakonhjemmet Hospital, Oslo, Norway. · College of Medical, Veterinary and Life Sciences, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. · Internal and Vascular Medicine, VU University Medical Center, Amsterdam, The Netherlands. · Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. · Department of Rheumatology, Paris Descartes University, Hôpital Cochin. Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris, France. · Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria. · IRCCS Galeazzi Orthopedic Institute, Milan, Italy. · Institute for Regional Health Research, University of Southern Denmark, Odense, Denmark. · Sygehus Sønderjylland (Hospital of Southern Jutland), Aabenraa, Denmark. · King Christian 10's Hospital for Rheumatic Diseases, Graasten, Denmark. · Department of Public Health and Clinical Medicine/Rheumatology, University of Umeå, Umeå, Sweden. · PARE (patient research partners), Sint-Joris-Weert, Belgium. · Romanian League Against Rheumatism (Vice-President) and Board Member (General Secretary) of AGORA, the Platform of S-E organisations for patients with RMDs, Bucharest, Romania. · Oslo University Hospital, Ullevål, Center for Preventive Medicine and Medical Faculty, University of Oslo, Oslo, Norway. · Department of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg and Section of Rheumatology, Lund, Sweden. · Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. · Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. · University of Cantabria, IDIVAL, Santander, Spain. · Head of Research and Development, Academic Affairs Dudley Group NHS Foundation Trust, Arthritis Research UK Centre for Epidemiology, University of Manchester, Russells Hall Hospital, Clinical Research Unit, Dudley, UK. · Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, University of Debrecen, Debrecen, Hungary. · Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK. · Department of Rheumatology and Musculoskeletal Epidemiology, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, UK. · Department of Rheumatology Reade, Amsterdam Rheumatology and Immunology Center, Reade & VU University Medical Center, Amsterdam, The Netherlands. ·Ann Rheum Dis · Pubmed #27697765.

ABSTRACT: Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.

3 Editorial The role of biologic therapy for psoriasis in cardiovascular risk reduction. 2017

No, Daniel J / Amin, Mina / Egeberg, Alexander / Wu, Jashin J. ·School of Medicine, Loma Linda University, California, USA. · School of Medicine, University of California, Riverside, USA. · Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Denmark. · Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, California, USA. ·Cutis · Pubmed #28319622.

ABSTRACT: -- No abstract --

4 Editorial Do "Evidence-Based Recommendations" Need to Reveal the Evidence? Minimal Criteria Supporting an "Evidence Claim". 2015

Christensen, Robin / Singh, Jasvinder A / Wells, George A / Tugwell, Peter S. ·Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; robin.christensen@regionh.dk. · Medicine Service, Birmingham VA Medical Center, Department of Medicine at School of Medicine, and Division of Epidemiology at School of Public Health, University of Alabama, Birmingham, AL; and Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA; · University of Ottawa Heart Institute, Ottawa, Canada; · School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Canada. ·J Rheumatol · Pubmed #26429204.

ABSTRACT: -- No abstract --

5 Editorial Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation? 2015

Kristensen, Søren Lund / McInnes, Iain B / Sattar, Naveed. ·BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK Department of Cardiology, Gentofte Hospital, Copenhagen, Denmark. · BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. ·Ann Rheum Dis · Pubmed #25429028.

ABSTRACT: -- No abstract --

6 Review Imaging in peripheral and axial psoriatic arthritis: contributions to diagnosis, follow-up, prognosis and knowledge of pathogenesis. 2018

Felbo, Sara K / Terslev, Lene / Østergaard, Mikkel. ·Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; and Dept. of Clinical Medicine, Faculty of Health and Medical Sciences, Univ. of Copenhagen, Copenhagen, Denmark. sara.helena.kamp@gmail.com. · Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark. · Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; and Dept. of Clinical Medicine, Faculty of Health and Medical Sciences, Univ. of Copenhagen, Copenhagen, Denmark. ·Clin Exp Rheumatol · Pubmed #30296988.

ABSTRACT: Imaging in psoriatic arthritis (PsA) is rapidly evolving, and the use of sensitive modalities both in clinical research and routine care is increasing. This article provides an overview of current knowledge of different imaging methods in PsA, including current and possible future use in diagnosis, prognosis and clinical management, value in understanding pathogenesis, and latest activities to establish responsive imaging outcome measures. Much research remains to be performed concerning imaging in PsA, particularly on its optimal use in routine clinical care, the clinical consequences of imaging-detected subclinical disease, and specific and sensitive PsA imaging outcome measures.

7 Review Comorbidities in vitiligo: comprehensive review. 2018

Dahir, Aisha M / Thomsen, Simon F. ·Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. · Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. ·Int J Dermatol · Pubmed #29808541.

ABSTRACT: Vitiligo is a common skin disorder characterized by idiopathic, progressive cutaneous hypomelanosis. Vitiligo is associated with several comorbid autoimmune, systemic, and dermatological diseases, primarily thyroid disease, alopecia areata, diabetes mellitus, pernicious anemia, systemic lupus erythematosus, rheumatoid arthritis, Addison's disease, inflammatory bowel disease, Sjögren's syndrome, dermatomyositis, scleroderma, ocular and audiological abnormalities, psoriasis, and atopic dermatitis. It is essential to increase awareness of these comorbidities in order to improve the disease burden and quality of life of patients with vitiligo. Herein, we review the association with the most frequent comorbidities associated with vitiligo.

8 Review The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review. 2018

Johansen, Cæcilie Bachdal / Jimenez-Solem, Espen / Haerskjold, Ann / Sand, Freja Lærke / Thomsen, Simon Francis. ·Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, 2400 Copenhagen NV, Denmark. cillebachdal@gmail.com. · Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, 2400 Copenhagen NV, Denmark. Espen.Jimenez.Solem@regionh.dk. · Department of Dermato-Venereology, Copenhagen University Hospital Bispebjerg, 2400 Copenhagen NV, Denmark. annhaerskjold@gmail.com. · Danish Cancer Society Research Center, 2100 Copenhagen Ø, Denmark. Frk.Sand@hotmail.com. · Department of Dermato-Venereology, Copenhagen University Hospital Bispebjerg, 2400 Copenhagen NV, Denmark. simon.francis.thomsen.02@regionh.dk. · Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen NV, Denmark. simon.francis.thomsen.02@regionh.dk. ·Int J Mol Sci · Pubmed #29751529.

ABSTRACT: Psoriasis is a chronic immune-mediated inflammatory disease affecting women of childbearing potential. Biologic agents, notably Tumor Necrosis Factor inhibitors (TNFi), are the only current non-contraindicated systemic treatment option during pregnancy. TNFi comprised of complete immunoglobulin G (IgG) antibodies antibodies (adalimumab, golimumab, and infliximab) actively cross the placenta from the second trimester and are detectable in the child up to one year postpartum. Data on safety of TNFi are conflicting; however a trend towards drug-specific harm has been reported, with increased risk of congenital malformations and preterm birth. TNFi exposure may alter the immune system of the infant towards hypersensitivity and reduced response to intracellular infections. Confounding by indication should be considered, as chronic inflammatory disease itself may pose a risk of adverse pregnancy outcomes. The quality of the current evidence is very low and no studies specifically address TNFi safety in women with psoriasis. Nonetheless, risks associated with TNFi treatment must be balanced against the as-yet uncertain risk of adverse outcomes in infants born to women with severe psoriasis. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. Herein, we present the current knowledge of the use and safety of TNFi during pregnancy in women with psoriasis.

9 Review [Comorbidity in connection with psoriasis is more than psoriatic arthritis]. 2018

Kvist-Hansen, Amanda / Kaiser, Hannah / Skov, Lone / Hansen, Peter Riis. ·prh@dadlnet.dk. ·Ugeskr Laeger · Pubmed #29368688.

ABSTRACT: Psoriasis is a common chronic inflammatory disease which is associated with extensive comorbidity, including psoriatic arthritis, cardiovascular and cardiometabolic disease, inflammatory bowel disease, malignancy, chronic kidney disease and depression. Clinical guidelines have been developed to target some of these comorbid diseases in patients with psoriasis and should be used by the treating physician.

10 Review The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. 2018

Sawyer, Laura / Fotheringham, Iain / Wright, Emily / Yasmeen, Najeeda / Gibbons, Carl / Holmen Møller, Anders. ·a Symmetron Ltd Kinetic Centre , Elstree , UK. · b LEO Pharma UK , Hurley Berkshire , UK. · c LEO Pharma Global , Ballerup , Denmark. ·J Dermatolog Treat · Pubmed #29323542.

ABSTRACT: PURPOSE: To evaluate the relative efficacy of brodalumab compared with approved biologic therapies and apremilast for moderate-to-severe psoriasis. METHODS: We searched MEDLINE, Embase, and Cochrane for randomized controlled trials reporting induction phase responses. The primary analysis examined the proportion of patients achieving Psoriasis Area Severity Index (PASI) 50, 75, 90, or 100 responses using a random-effects Bayesian multinomial likelihood model with probit link, with and without adjustment for variation in study-level placebo responses. RESULTS: A total of 54 studies were included. Based on PASI 100 response, the most efficacious therapies were brodalumab 210 mg every two weeks (Q2W) and ixekizumab. Brodalumab 210 mg Q2W was significantly more efficacious than adalimumab, apremilast, brodalumab 140 mg Q2W, etanercept, infliximab, secukinumab, and ustekinumab. Results were consistent for PASI 50, 75, and 90 outcomes and all sensitivity analyses. CONCLUSIONS: Our findings are consistent with pivotal trials which indicate that high levels of complete clearance can be achieved with brodalumab. Based on existing evidence, induction-phase efficacy of brodalumab is similar to ixekizumab and superior to other approved therapies, including anti-TNFs, apremilast, secukinumab, and ustekinumab.

11 Review A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. 2018

Højgaard, Pil / Klokker, Louise / Orbai, Ana-Maria / Holmsted, Kim / Bartels, Else M / Leung, Ying Ying / Goel, Niti / de Wit, Maarten / Gladman, Dafna D / Mease, Philip / Dreyer, Lene / Kristensen, Lars E / FitzGerald, Oliver / Tillett, William / Gossec, Laure / Helliwell, Philip / Strand, Vibeke / Ogdie, Alexis / Terwee, Caroline B / Christensen, Robin. ·The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57, DK-2000, Copenhagen, Denmark; Department of Rheumatology, Rigshospitalet, Gentofte Hospital, Kildegaardsvej 28, 2900 Hellerup, Denmark. · The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57, DK-2000, Copenhagen, Denmark. · Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD. · Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Rd, the Academia, S169856, Singapore. · Division of Rheumatology, Duke University School of Medicine, Advisory Services, QuintilesIMS, Durham, NC. · VU University Amsterdam, Department of Medical Humanities, Amsterdam, the Netherlands. · Division of Rheumatology and Krembil Research Institute, University Health Network, Toronto Western Hospital, 399 Bathurst St, 1E-410B, Toronto, Ontario, Canada M5T 2S8. · Division of Rheumatology Clinical Research, Swedish Medical Center, Seattle, WA. · Department of Rheumatology, St Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Ireland. · Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Pharmacy and Pharmacology, University of Bath, Bath, UK. · Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitie-Salpétrière Hospital, AP-HP, Rheumatology Department, 47-83 Bd de l'Hopital, Paris 75013, France. · Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Harehills Lane, Leeds LS7 4SA, UK. · Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA. · Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. · VU University Medical Center, Department of Epidemiology and Biostatistics and Amsterdam Public Health Research Institute, Amsterdam, the Netherlands. · The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57, DK-2000, Copenhagen, Denmark. Electronic address: Robin.christensen@regionh.dk. ·Semin Arthritis Rheum · Pubmed #29037523.

ABSTRACT: BACKGROUND: An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized controlled trials (RCTs) was endorsed at the Outcome Measures in Rheumatology (OMERACT) meeting in 2016. OBJECTIVES: To synthesize the evidence on measurement properties of patient reported outcome measures (PROMs) for PsA and thereby contribute to development of a PsA core outcome measurement set (COMS) as described by the OMERACT Filter 2.0. METHODS: A systematic literature search was performed in EMBASE, MEDLINE and PsycINFO on Jan 1, 2017 to identify full-text articles with an aim of assessing the measurement properties of PROMs in PsA. Two independent reviewers rated the quality of studies using the COnsensus based standards for the Selection of health Measurement INstruments (COSMIN) checklist, and performed a qualitative evidence synthesis. RESULTS: Fifty-five studies were included in the systematic review. Forty-four instruments and a total of 89 scales were analyzed. PROMs measuring COS domains with at least fair quality evidence for good validity and reliability (and no evidence for poor properties) included the Stockerau Activity Score for PsA (German), Psoriasis Symptom Inventory, visual analogue scale for Patient Global, 36 Item Short Form Health Survey Physical Function subscale, Health Assessment Questionnaire Disability Index, Bath Ankylosing Spondylitis Functional Index, PsA Impact of Disease questionnaire, PsA Quality of Life questionnaire, VITACORA-19, Functional Assessment of Chronic Illness Therapy Fatigue scale and Social Role Participation Questionnaire. CONCLUSIONS: At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight mandatory domains of the PsA COS.

12 Review eHealth Technologies as an intervention to improve adherence to topical antipsoriatics: a systematic review. 2018

Svendsen, Mathias Tiedemann / Andersen, Flemming / Andersen, Klaus Ejner. ·a Department of Dermatology and Allergy Centre , Odense University Hospital , Odense C , Denmark. · b Dermatological Investigations Scandinavia , Odense C , Denmark. · c Centre for Innovative Medical Technology , Institute of Clinical Research, University of Southern Denmark , Odense C , Denmark. ·J Dermatolog Treat · Pubmed #28604138.

ABSTRACT: BACKGROUND: Topical antipsoriatics are recommended first-line treatment of psoriasis, but rates of adherence are low. Patient support by use of electronic health (eHealth) services is suggested to improve medical adherence. OBJECTIVE: To review randomised controlled trials (RCTs) testing eHealth interventions designed to improve adherence to topical antipsoriatics and to review applications for smartphones (apps) incorporating the word psoriasis. MATERIAL AND METHODS: Literature review: Medline, Embase, Cochrane, PsycINFO and Web of Science were searched using search terms for eHealth, psoriasis and topical antipsoriatics. General analysis of apps: The operating systems (OS) for smartphones, iOS, Google Play, Microsoft Store, Symbian OS and Blackberry OS were searched for apps containing the word psoriasis. RESULTS: Literature review: Only one RCT was included, reporting on psoriasis patients' Internet reporting their status of psoriasis over a 12-month period. The rate of adherence was measured by Medication Event Monitoring System (MEMS CONCLUSION: There is a critical need for high-quality RCTs testing if the ubiquitous eHealth technologies, for example, some of the numerous apps, can improve psoriasis patients' rates of adherence to topical antipsoriatics.

13 Review Old and New Biological Therapies for Psoriasis. 2017

Rønholt, Kirsten / Iversen, Lars. ·Department of Dermatology, Aarhus University Hospital, 8000 Aarhus, Denmark. kitepeer@rm.dk. · Department of Dermatology, Aarhus University Hospital, 8000 Aarhus, Denmark. lars.iversen@clin.au.dk. ·Int J Mol Sci · Pubmed #29104241.

ABSTRACT: Biological therapy became available for psoriasis with the introduction of alefacept at the beginning of this century. Up to then, systemic treatment options comprised small molecule drugs, targeting the immune system in a non-specific manner. The first biologics targeted T-cell activation and migration and served as an alternative to small molecules. However, significant improvement in outcome was first accomplished with the introduction of tumor necrosis factor-α inhibitors that were already approved for other inflammatory disorders, including rheumatic diseases. Along with the progress in understanding psoriasis pathogenesis, highly targeted and effective therapies have since developed with the perspective not only to improve but to clear psoriasis. These accomplishments enable future achievement of advanced goals to individualize treatment best suited for each patient. Mechanistic studies with patients treated with the new highly targeted biologics may guide us towards these goals. This review offers an overview of biologics developed for psoriasis and illustrate a historical progress in the treatment of this common chronic inflammatory skin condition.

14 Review Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases. 2017

Havmose, Martin / Thomsen, Simon Francis. ·Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. · Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. ·Int J Dermatol · Pubmed #28737221.

ABSTRACT: BACKGROUND: TNF inhibitors have proven to be effective and relatively safe in the management of psoriasis. While infections and certain malignancies are established as acknowledged side effects, paradoxical inflammatory, non-neoplastic, noninfectious adverse events are being recognized less frequently. We aimed to identify published, peer-reviewed cases of paradoxical inflammatory, non-neoplastic, noninfectious adverse events in psoriasis patients during TNF inhibitor therapy. METHODS: A literature search in MEDLINE was performed for articles published from inception through the 8th of June 2016 that reported suspected incidents fulfilling a predefined search strategy. In addition, articles identified by reference lists were added. RESULTS: A total of 295 cases from various organ systems among 13 269 patients were identified: 91 cases were related to infliximab, 101 cases were related to etanercept, and 102 cases were related to adalimumab. One case report was related to both etanercept and adalimumab. CONCLUSION: Induction of paradoxical non-neoplastic noninflammatory adverse events in psoriasis patients treated with a TNF inhibitor is worth recognizing. The amount of cases identified by this study suggests that continuous surveillance and research into these adverse effects is relevant. Nondermatologic paradoxical inflammatory reactions may be underreported.

15 Review Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. 2017

Cohen, A D / Wu, J J / Puig, L / Chimenti, S / Vender, R / Rajagopalan, M / Romiti, R / de la Cruz, C / Skov, L / Zachariae, C / Young, H S / Foley, P / van der Walt, J M / Naldi, L / Prens, E P / Blauvelt, A. ·Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. · Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel. · Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, U.S.A. · Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. · University of Rome Tor Vergata, Rome, Italy. · Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada. · Department of Dermatology, Apollo Hospitals, Chennai, India. · Department of Dermatology, University of São Paulo, São Paulo, Brazil. · Clínica Dermacross, Santiago, Chile. · Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. · The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K. · Department of Dermatology, Salford Royal NHS Foundation Trust, Manchester, U.K. · Skin & Cancer Foundation Inc., Carlton, Vic., Australia. · Department of Dermatology, The University of Melbourne, Melbourne, Vic., Australia. · St Vincent's Hospital, Melbourne, Vic., Australia. · International Psoriasis Council, St Louis, MO, U.S.A. · Department of Dermatology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. · Deptartment of Dermatology, Erasmus MC, P.O. Box 5201, 3008, AE Rotterdam, the Netherlands. · Oregon Medical Research Center, Portland, OR, U.S.A. ·Br J Dermatol · Pubmed #28646580.

ABSTRACT: The introduction of biological drugs for the treatment of patients with psoriasis has revolutionized treatment paradigms and enabled numerous patients to achieve disease control with an acceptable safety profile. However, the high cost of biologics limits access to these medications for the majority of patients worldwide. In recent years, the introduction of biosimilars for inflammatory diseases has become a fast evolving field. The future use of biosimilars offers the potential for decreased cost and increased access to biologics for patients with psoriasis. For approval of biosimilars, different regulatory agencies use highly variable methods for definition, production, approval, marketing and postmarketing surveillance. Due to potential interchangeability between biologics and biosimilars, traceability and pharmacovigilance are required to collect accurate data about adverse events in patients with psoriasis; spontaneous reporting, registries and use of 'big data' should facilitate this process on a global basis. The current article describes biosimilar regulatory guidelines and examples of biosimilar uptake in clinical practice in several countries around the world. As it is apparent that biological therapy treatment decisions may become more physician independent, the International Psoriasis Council recommends that dermatologists should take an active role in the development of biosimilar prescribing policies with their respective healthcare settings and government agencies.

16 Review Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. 2017

Iversen, L / Dauden, E / Segaert, S / Freeman, K / Magina, S / Rigopoulos, D / Thaci, D. ·Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark. · Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain. · Department of Dermatology, University Hospital Leuven, Leuven, Belgium. · Bunny Hill Primary Care Centre, County Durham and Darlington NHS Foundation Trust & Sunderland Teaching Primary Care Trust, Sunderland, UK. · Department of Dermatology, CHSJoão, Porto, Portugal. · Department of Pharmacology and Therapeutics, Faculty of Medicine, Porto University, Porto, Portugal. · 2nd Department of Dermatology, University of Athens Medical School, Attikon Hospital, Athens, Greece. · Comprehensive Centre for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany. ·J Eur Acad Dermatol Venereol · Pubmed #28419600.

ABSTRACT: Although the majority of patients with psoriasis vulgaris are treated exclusively with topical therapies, research to develop more effective topical therapies that are associated with higher patient satisfaction has lagged behind the development of systemic agents. The aim of this literature review was to determine whether there is documented evidence that applying an innovative approach to improving the formulation of active ingredients commonly used in the topical treatment of psoriasis can have a positive effect on clinical outcomes and patient-reported outcomes (PROs). The Embase and PubMed databases were searched for articles published between 2001 and 2016 that made direct head-to-head comparisons of different formulations of an active pharmaceutical ingredient (API), focusing on clinical outcomes and PROs. In total, 22 publications on APIs or API combinations met the eligibility criteria (19 head-to-head clinical trials, one pooled analysis, one health-economic modelling study and one systematic review). Significant clinical benefit associated with the use of a reformulated API over an older formulation was reported in three trials of clobetasol propionate, one trial of calcipotriol, three trials of betamethasone and five trials/pooled analyses of calcipotriol/calcipotriene + betamethasone dipropionate (Cal/BD) formulations. Significantly improved PROs associated with the use of a reformulated API over an older formulation were reported in three trials of clobetasol propionate, one trial of betamethasone valerate and two trials of Cal/BD formulations. These results demonstrate that the innovative reformulation of APIs used in the treatment of psoriasis can produce therapies that attain significantly improved clinical outcomes and PROs. This suggests that improvement in topical therapy for psoriasis need not only to be achieved by the identification of new targets and the development of new APIs, but that improvement in the vehicle used to deliver existing APIs has the potential to result in significant clinical and patient benefits.

17 Review Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne. 2017

Vinkel, Caroline / Thomsen, Simon F. ·Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. · Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. ·Int J Dermatol · Pubmed #28345207.

ABSTRACT: Autoinflammatory syndromes associated with hidradenitis suppurativa (HS) and/or acne are rare but potentially debilitating disorders if not diagnosed and treated correctly. They share a common pathogenesis involving a dysregulated innate immune system with abnormal interleukin (IL)-1 signaling leading to sterile neutrophilic inflammation. The clinical features are recurrent episodes of fever, painful arthritis, and skin lesions consistent with HS, acne, and pyoderma gangrenosum (PG) accompanied by elevated systemic inflammatory markers in blood. So far, several clinically different syndromes have been reported in the literature including pyoderma gangrenosum, acne, and pyogenic arthritis (PAPA), pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH), pyoderma gangrenosum, acne, and spondyloarthritis (PASS), pyoderma gangrenosum, acne, pyogenic arthritis, and hidradenitis suppurativa (PAPASH), psoriatic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PsAPASH), and pyoderma gangrenosum, acne, and ulcerative colitis (PAC). The rarity of the syndromes complicates the establishment of evidence-based treatment guidelines. Furthermore, treatment can be challenging due to lack of response to standard treatment modalities. Therefore, it is important to increase the awareness about these diseases in order to optimize disease management and ultimately improve the quality of life of patients.

18 Review Health-related Quality of Life in Children and Adolescents with Psoriasis: A Systematic Review and Meta-analysis. 2017

Randa, Hilde / Todberg, Tanja / Skov, Lone / Larsen, Lotte S / Zachariae, Robert. ·Unit of Psychooncology and Health Psychology, Department of Oncology, Aarhus University Hospital, DK-8000 Aarhus, Denmark. hilderanda@psy.au.dk. ·Acta Derm Venereol · Pubmed #27983745.

ABSTRACT: Studies demonstrating the negative impact of paediatric psoriasis on health-related quality of life (HRQOL) are accumulating, but little is known about moderators of HRQOL. The objectives of this review were to summarize studies on HRQOL in paediatric psoriasis and to explore the potential moderating influences of demographic and clinical variables. Searches were conducted by 2 independent researchers in PubMed, Embase, CINAHL, PsycINFO, and Scopus for papers published between 1995 (the date the first dermatology-specific HRQOL-instrument for children was introduced) and 2016. Eligible studies were required to report HRQOL data for children and/or adolescents with psoriasis (4-18 years) using validated HRQOL questionnaires. Seven-teen eligible studies (number of patients=1,185) were identified. Moderation analyses revealed that study samples with a higher percentage of girls were associated with better HRQOL (β = 0.19), while a higher mean age of onset (β = 0.83) and study quality (β = 0.28) were associated with lower HRQOL (all p<0.05). Several papers did not provide the information necessary for exploring between-study differences, thus the moderation analysis results should be interpreted with caution. In conclusion, children and adolescents with psoriasis experience moderate impairment of HRQOL. Certain demographic characteristics (e.g. sex) and clinical characteristics (e.g. age at onset) appear to moderate this impact.

19 Review Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. 2017

Paul, Carle / Bang, Bo / Lebwohl, Mark. ·a Professor and Chairman of the Department of Dermatology , Paul Sabatier University and Larrey Hospital , Toulouse , France. · b Medical Lead, Skin inflammation Projects , LEO Pharma A/S , Ballerup , Denmark. · c Professor and System Chair of the Department of Dermatology , Icahn School of Medicine at Mount Sinai , New York , NY , USA. ·Expert Opin Pharmacother · Pubmed #27936972.

ABSTRACT: INTRODUCTION: Psoriasis is a chronic, immune-mediated inflammatory disorder with a significant negative impact on quality of life. Most patients with mild-to-moderate psoriasis manage their disease with topical therapies; the most commonly used formulations contain corticosteroids and/or vitamin D3 analogues. However, adherence to topical treatment remains a significant issue as the daily treatment regimen can be cumbersome and time consuming and many patients do not obtain complete/almost complete clearance. Areas covered: Published pre-clinical and clinical data evaluating calcipotriol 50 µg/g (Cal) and betamethasone 0.5 mg/g as dipropionate (BD) aerosol foam in patients with psoriasis. Expert opinion: Cal/BD aerosol foam, a once-daily, alcohol-free, paraffin-based vehicle with emollient properties, was developed to increase the therapeutic options available to patients. Cal/BD aerosol foam is rapidly effective for treating psoriasis and the greater efficacy compared with the ointment and gel formulations is consistent and clinically relevant. This enhanced efficacy is due to improved skin penetration of the active ingredients following the formation of a stable supersaturated solution on the skin. Studies have shown increasing patient satisfaction with Cal/BD aerosol foam. It is hoped that this optimized formulation of Cal/BD will improve adherence and help to address the unmet medical needs of patients with mild-to-moderate psoriasis.

20 Review Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. 2017

Svendsen, Mathias Tiedemann / Jeyabalan, Janithika / Andersen, Klaus Ejner / Andersen, Flemming / Johannessen, Helle. ·a Department of Dermatology and Allergy Centre , Odense University Hospital , Odense C , Denmark. · b Dermatological Investigations Scandinavia, University of Southern Denmark , Odense C , Denmark. · c Centre for Innovative Medical Technology , Institute of Clinical Research, University of Southern Denmark , Odense C , Denmark. · d Research Unit of User Perspectives, Department of Public Health , University of Southern Denmark , Odense C , Denmark. ·J Dermatolog Treat · Pubmed #27786594.

ABSTRACT: OBJECTIVE: To review published literature describing the global use of topical antipsoriatics. MATERIALS AND METHODS: Search for English-language articles in Embase, Pubmed, PsycINFO and Cochrane Library. RESULTS: Fifty-four selected publications were found, describing psoriasis patients' use of topical antipsoriatics, using six different methods to collect data. The eight most frequently used topical treatments from the regions North/South America, North/Central/South Europe, Asia, Middle East and Australia were: corticosteroids used by 16-79%, complementary and alternative medicines used by 10-62%, phototherapies used by 0.4-75%, calcipotriol used by 4.2-73%, corticosteroid/calcipotriol combinations used by 3.3-71%, tar used by 0.8-66%, anthralin used by 15% and emollients used as monotherapy by 1-23%. Rates of patient-reported adherence to topical remedies ranged from 51% to 90% and rates of patient-reported satisfaction with topical as it pertains to symptom control ranged from 12% to 52%. CONCLUSION: The identified use patterns are varying and reflect a lack of data from large parts of the world and noncomparable studies using heterogeneous study designs. However, this study emphasizes the importance of medical professionals involvement of the patient with respect to choosing prescribed topical treatment and the possibility of patients' use of alternative treatments. More drug utilization studies, both survey and register based, from different parts of the world are needed to provide more conclusive evidence about patients' use of topical antipsoriatics.

21 Review Biosimilars for psoriasis: clinical studies to determine similarity. 2017

Blauvelt, A / Puig, L / Chimenti, S / Vender, R / Rajagopalan, M / Romiti, R / Skov, L / Zachariae, C / Young, H / Prens, E / Cohen, A / van der Walt, J / Wu, J J. ·Oregon Medical Research Center, Portland, OR, U.S.A. · Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. · University of Rome Tor Vergate, Rome, Italy. · Dermatrials Research Inc., Hamilton, ON, Canada. · Venderm Innovations in Psoriasis, Hamilton, ON, Canada. · Apollo Hospitals, Chennai, India. · Department of Dermatology, University of São Paulo, São Paulo, Brazil. · Herllev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. · Manchester Academic Health Science Centre, Department of Dermatology, University of Manchester, Salford Royal Hospital, Manchester, U.K. · Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. · Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. · Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel. · International Psoriasis Council, St Louis, MO, U.S.A. · Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, U.S.A. ·Br J Dermatol · Pubmed #27639072.

ABSTRACT: Biosimilars are drugs that are similar, but not identical, to originator biologics. Preclinical analytical studies are required to show similarity on a molecular and structural level, but efficacy and safety studies in humans are essential to determining biosimilarity. In this review, written by members of the International Psoriasis Council, we discuss how biosimilars are evaluated in a clinical setting, with emphasis on extrapolation of indication, interchangeability and optimal clinical trial design.

22 Review Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. 2017

Saunte, D M / Mrowietz, U / Puig, L / Zachariae, C. ·Department of Dermatology, Zealand University Hospital, Roskilde, Denmark. · Psoriasis Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany. · Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. · Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. ·Br J Dermatol · Pubmed #27580411.

ABSTRACT: The recognition of the central role of interleukin (IL)-17A in the pathogenesis of psoriasis has led to the development of several monoclonal antibodies targeting this cytokine or its receptors for therapeutic purposes. IL-17A also plays an important role in immunological protection against infections, especially those due to Candida spp., as evidenced by findings in patients with genetic defects in IL-17-related immune responses. To assess the potential of anti-IL-17 treatment to promote Candida infections, here we have systematically reviewed published clinical trials of patients with psoriasis or psoriatic arthritis. Candida infections were reported in 4·0% of patients treated with brodalumab, 1·7% with secukinumab and 3·3% with ixekizumab vs. 0·3%, 2·3% and 0·8% of those assigned to placebo, ustekinumab or etanercept, respectively. Although the incidence of Candida infection was found to be increased by only a small degree during anti-IL-17 therapy, patients undergoing such treatment should be monitored for fungal infection and treated as necessary. We propose adoption of the recently updated recommendations for the practical management of Candida infection in patients administered IL-17 inhibitors.

23 Review Co-morbidity in psoriasis: mechanisms and implications for treatment. 2017

Lønnberg, Ann Sophie / Skov, Lone. ·a Department of Dermato-Allergology, Herlev and Gentofte Hospital , University of Copenhagen , Hellerup , Denmark. ·Expert Rev Clin Immunol · Pubmed #27426230.

ABSTRACT: INTRODUCTION: Psoriasis is a common, chronic, immune-mediated inflammatory disorder. The disease is associated with several co-morbidities including cardiovascular disease, metabolic syndrome, and psychiatric disorders. It is important to identify and treat these co-morbidities because they have a strongly negative effect on the overall health of patients with psoriasis. Unfortunately, these co-morbidities are often overlooked and/or left untreated. Therefore, the aim of this review is to discuss the mechanisms of how co-morbidities are associated with psoriasis as well as implications for the clinic to be able to recognize such co-morbidities. Areas covered: This is a review of studies investigating and discussing co-morbidities of psoriasis and screening. Literature was retrieved by searching on the PubMed database using individual and combined search terms related to relevant co-morbidities. Expert commentary: Effective management of psoriasis involves targeting of both psoriasis and co-morbidities.

24 Review Medical adherence to topical corticosteroid preparations prescribed for psoriasis: A systematic review. 2017

Svendsen, Mathias Tiedemann / Andersen, Flemming / Hansen, Jakob / Johannessen, Helle / Andersen, Klaus Ejner. ·a Department of Dermatology and Allergy Centre , Odense University Hospital , Odense C , Denmark. · b Centre for Innovative Medical Technology, Institute of Clinical Research, University of Southern Denmark , Odense C , Denmark. · c Dermatological Investigations Scandinavia , Odense C , Denmark. · d Leo Pharma , Ballerup , Denmark. · e Research Unit of User Perspectives, Department of Public Health , University of Southern Denmark , Odense C , Denmark. ·J Dermatolog Treat · Pubmed #27151546.

ABSTRACT: OBJECTIVE: Topical corticosteroids and corticosteroid combinations are the principal treatments in psoriasis. The aim of this study was to investigate published literature dealing with medical adherence to topical corticosteroid or corticosteroid combinations in patients with psoriasis. MATERIALS AND METHODS: Systematic electronic searches in English language literature were done until September 2015 without publication date restriction. RESULTS: We identified 11 studies consisting of five surveys, two prospective studies, one qualitative study, one mixed-method study, one register study, and one interventional study. Observation periods varied and rates of nonadherence ranged from 8% to 88.3%. The rates were reported by patients on eight nonvalidated scales and one validated scale, measured by medication weight in two studies, and in two studies rates of nonadherence were measured using prescription registers. Thirty-four multifactorial determinants of nonadherence were found. One designed intervention consisted of a disease management program, which improved adherence in the study period. Overall, the studies included were heterogeneous in design and had a high risk of bias. CONCLUSION: To improve health outcome in topical treatment of psoriasis, further studies should be conducted addressing determinants of nonadherence and test interventions to improve adherence. Validated measurements of medical nonadherence, prescription registers, or medication-weight are needed.

25 Review Psoriasis and Obesity. 2016

Jensen, Peter / Skov, Lone. ·Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark. ·Dermatology · Pubmed #28226326.

ABSTRACT: Psoriasis is a common chronic inflammatory skin disease with a complex pathogenesis consisting of a genetic component, immune dysfunction, and environmental factors. It is associated with numerous comorbidities including psoriatic arthritis, cardiovascular disease, metabolic syndrome, and obesity. Evidence suggests that obesity is a risk factor for incident psoriasis, aggravates existing psoriasis, and that weight reduction may improve the severity of psoriasis in overweight individuals. Excess body weight may interfere with the medical treatment used in psoriasis and adds to the cardiovascular risk profile in these patients, which underscores the importance of effective weight control regimens. In this review we examine the current literature with regard to the association between obesity and psoriasis.

Next